Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.
Erin Murphy, MD, radiation oncologist, Cleveland Clinic, discusses the clinical implications of pazopanib (Votrient) plus stereotactic body radiotherapy (SBRT) in pediatric sarcoma.
Findings from a retrospective study of 10 heavily pretreated pediatric patients with metastatic sarcoma, including those with bone, lung, and soft tissue metastases, showed that the combination of pazopanib and SBRT was safe and tolerable.
Having a well-tolerated combination of systemic therapy and localized therapy is important for this heavily pretreated population, says Murphy. These patients tend to be among the most fragile and have typically progressed on at least 2 prior regimens before receiving pazopanib, Murphy explains. Because patients have likely had significant bone marrow suppression, utilizing high-dose SBRT is a good option that doesn’t treat a lot of bone marrow, Murphy concludes.